tnip2 sirna  (Ribobio co)

Journal: Experimental and Therapeutic Medicine

Article Title: Role of microRNA-15a-5p/TNFAIP3-interacting protein 2 axis in acute lung injury induced by traumatic hemorrhagic shock

doi: 10.3892/etm.2020.9130

Figure Lengend Snippet: TNIP2 is a direct target of miR-15a-5p. (A) Interaction between miR-15a-5p and 3'UTR of TNIP2 was predicted using TargetScan. (B) Luciferase activity of a reporter containing a wild-type TNIP2 3'UTR or a mutant TNIP2 3' UTR are presented. TNIP2-MUT indicates the TNIP2 3' UTR with a mutation in the miR-15a-5p binding site. All data are presented as the mean ± SD of three independent experiments. ** P<0.01 vs. mimic control. miR, microRNA; UTR, untranslated region; THS, traumatic hemorrhagic shock; WT, wild type; TNIP2, TNFAIP3-interacting protein 2.

Article Snippet: Rats were intraperitoneally injected with inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day) + TNIP2-siRNA (80 mg/kg/day; cat. no. sc-44638; Santa Cruz Biotechnology, Inc.) prior to surgery using in vivo transfection reagent (EntransterTM- in vivo ; Engreen Biosystem Co., Ltd.).

Techniques: Luciferase, Activity Assay, Mutagenesis, Binding Assay

Journal: Experimental and Therapeutic Medicine

Article Title: Role of microRNA-15a-5p/TNFAIP3-interacting protein 2 axis in acute lung injury induced by traumatic hemorrhagic shock

doi: 10.3892/etm.2020.9130

Figure Lengend Snippet: Expression level of TNIP2 in patients with THS and rats. (A) mRNA and (B) protein level of TNIP2 in the blood of patients with THS was detected using RT-qPCR and western blotting (C1, C2: Healthy control; T1-T4: Patients with THS). (C) mRNA and (D) protein level of TNIP2 in the blood of THS rats was detected using RT-qPCR and western blotting. (E) mRNA and (F) protein level of TNIP2 in the lung tissues of THS rats was detected using RT-qPCR and western blotting. Data were expressed as mean ± SD. ** P<0.01 vs. control group. THS, traumatic hemorrhagic shock; TNIP2, TNFAIP3-interacting protein 2; RT-qPCR, reverse transcription-quantitative PCR.

Article Snippet: Rats were intraperitoneally injected with inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day) + TNIP2-siRNA (80 mg/kg/day; cat. no. sc-44638; Santa Cruz Biotechnology, Inc.) prior to surgery using in vivo transfection reagent (EntransterTM- in vivo ; Engreen Biosystem Co., Ltd.).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Real-time Polymerase Chain Reaction

Journal: Experimental and Therapeutic Medicine

Article Title: Role of microRNA-15a-5p/TNFAIP3-interacting protein 2 axis in acute lung injury induced by traumatic hemorrhagic shock

doi: 10.3892/etm.2020.9130

Figure Lengend Snippet: Effect of miR-15a-5p on TNIP2 expression in THS rats. Rats were intraperitoneally injected with inhibitor control, or miR-15a-5p inhibitor prior to THS induction. After 24 h, the level of miR-15a-5p and TNIP2 in the blood and lung tissues of THS rats was determined. The level of miR-15a-5p in the (A) blood and (B) lung tissue of THS rats was detected using RT-qPCR. The TNIP2 mRNA level in the (C) blood and (D) lung tissue of THS rats was detected using RT-qPCR: The mRNA and protein level of TNIP2 in the blood of THS rats was detected using (E) RT-qPCR and (F) western blotting. The mRNA and protein level of TNIP2 in the lung tissues of THS rats was detected using (G) RT-qPCR and (H) western blotting. Data were expressed as mean ± SD. ** P<0.01 vs. control group. miR, microRNA; THS, traumatic hemorrhagic shock; TNIP2, TNFAIP3-interacting protein 2; RT-qPCR, reverse transcription-quantitative PCR.

Article Snippet: Rats were intraperitoneally injected with inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day) + TNIP2-siRNA (80 mg/kg/day; cat. no. sc-44638; Santa Cruz Biotechnology, Inc.) prior to surgery using in vivo transfection reagent (EntransterTM- in vivo ; Engreen Biosystem Co., Ltd.).

Techniques: Expressing, Injection, Quantitative RT-PCR, Western Blot, Real-time Polymerase Chain Reaction

Journal: Experimental and Therapeutic Medicine

Article Title: Role of microRNA-15a-5p/TNFAIP3-interacting protein 2 axis in acute lung injury induced by traumatic hemorrhagic shock

doi: 10.3892/etm.2020.9130

Figure Lengend Snippet: Effect of miR-15a-5p on pro-inflammatory factors production in THS rats. The levels of TNF-α in (A) BALF and (B) serum and the levels of IL-6 in (C) BALF and (D) serum in rats were detected using ELISA. Data are expressed as mean ± SD. ** P<0.01 vs. control group; ## P<0.01 vs. THS group; && P<0.01 vs. inhibitor group. miR, microRNA; THS, traumatic hemorrhagic shock; TNIP2, TNFAIP3-interacting protein 2; BALF, bronchoalveolar lavage fluid; IL, interleukin; TNF-α, tumor necrosis factor-α; siRNA, small interfering RNA.

Article Snippet: Rats were intraperitoneally injected with inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day) + TNIP2-siRNA (80 mg/kg/day; cat. no. sc-44638; Santa Cruz Biotechnology, Inc.) prior to surgery using in vivo transfection reagent (EntransterTM- in vivo ; Engreen Biosystem Co., Ltd.).

Techniques: Enzyme-linked Immunosorbent Assay, Small Interfering RNA

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: TNIP2 is a direct target of miR-15a-5p. (A) The binding sites between miR-15a-5p and TNIP2 3'-UTR. (B) Dual-luciferase reporter assays were performed to measure the luciferase activities. * * P<0.01 vs. mimic control. (C) Inhibitor control or miR-15a-5p inhibitor was transfected into RAW264.7 macrophages for 48 h to detect the mRNA levels of miR-15a-5p. Control-siRNA or TNIP2-siRNA was transfected into RAW264.7 macrophages for 48 h to detect the TNIP2 (D) mRNA and (E) protein levels. Following transfection with miR-15a-5p inhibitor, inhibitor control, or miR-15a-5p inhibitor + TNIP2-siRNA, the (F) mRNA and (G) protein expression level of TNIP2 in RAW264.7 macrophages was measured. ## P<0.01 vs. inhibitor control; && P<0.01 vs. control-siRNA; $$ P<0.01 vs. inhibitor. miR, microRNA; MUT, mutant; LPS, lipopolysaccharide; siRNA, small interfering RNA; TNIP, tumor necrosis factor-α induced protein 3-interacting protein; WT, wild-type; UTR, untranslated region.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Binding Assay, Luciferase, Transfection, Expressing, Mutagenesis, Small Interfering RNA

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: Expression of TNIP2 is suppressed in RAW264.7 macrophages following LPS treatment. (A) The mRNA expression levels of TNIP2 were reduced in RAW264.7 macrophages treated with LPS. (B) The protein levels of TNIP2 were detected by western blot analysis in RAW264.7 macrophages following LPS treatment. * * P<0.01 vs. control. LPS, lipopolysaccharide; TNIP, tumor necrosis factor-α induced protein 3-interacting protein.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Expressing, Western Blot

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: miR-15a-5p downregulation suppresses the LPS-induced inflammatory factors released in RAW264.7 macrophages. RAW264.7 macrophage cells were transfected with or without inhibitor control, miR-15a-5p inhibitor or miR-15a-5p inhibitor + TNIP2-siRNA for 48 h, and cells were subsequently stimulated with 1 µg/ml LPS for 4 h. The expression levels of inflammatory factors (A) IL-1β, (B) IL-6 and (C) TNF-α in cells from the various treatment groups were detected using ELISAs. * * P<0.01 vs. control; ## P<0.01 vs. LPS+inhibitor control; && P<0.01 vs. LPS+inhibitor. LPS, lipopolysaccharide; miR, microRNA; IL, interleukin; siRNA, small interfering RNA; TNF, tumor necrosis; TNIP, TNF-α induced protein 3-interacting protein.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Transfection, Expressing, Small Interfering RNA

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: miR-15a-5p inhibitor inhibits LPS-induced NF-κ activation in RAW264.7 macrophages and TNIP2-siRNA reverses the effects. RAW264.7 macrophage cells were transfected with or without inhibitor control, miR-15a-5p inhibitor or miR-15a-5p inhibitor + TNIP2-siRNA for 48 h, and cells were stimulated with 1 µg/ml LPS for 4 h. (A) Protein expression level of p-p65 and p65 was detected using western blot assays. (B) The ratio of p-p65/p65. * * P<0.01 vs. control; ## P<0.01 vs. LPS+inhibitor control; && P<0.01 vs. LPS+inhibitor. LPS, lipopolysaccharide; miR, microRNA; p, phosphorylated; siRNA, small interfering RNA; TNIP, tumor necrosis factor-α induced protein 3-interacting protein.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Activation Assay, Transfection, Expressing, Western Blot, Small Interfering RNA

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: Effect of miR-15a-5p inhibitor and TNIP2-siRNA on miR-15a-5p and TNIP2 expression in mice. (A) The level of miR-15a-5p in the serum of mice was detected using RT-qPCR. (B) The mRNA level of TNIP2 in the serum of mice was detected using RT-qPCR. * * P<0.01 vs. inhibitor control; ## P<0.01 vs. control-siRNA. miR, microRNA; siRNA, small interfering RNA; RT-qPCR, reverse transcription-quantitative PCR.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Expressing, Quantitative RT-PCR, Small Interfering RNA, Real-time Polymerase Chain Reaction

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: TNIP2-siRNA eliminates the effects of miR-15a-5p inhibitor in LPS-induced septic mice. The serum (A) IL-1β, (B) IL-6 and (C) TNF-α levels were evaluated using ELISAs. The serum (D) Cr, (E) BUN, (F) ALT and (G) AST levels were evaluated in the various treatment groups. * * P<0.01 vs. LPS+inhibitor control; ## P<0.01 vs. LPS+inhibitor. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatine; LPS, lipopolysaccharide; miR, microRNA; IL, interleukin; siRNA, small interfering RNA; TNF, tumor necrosis factor; TNIP, TNF-α induced protein 3-interacting protein.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Small Interfering RNA

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: TNIP2 is a direct target of miR-15a-5p. (A) The binding sites between miR-15a-5p and TNIP2 3'-UTR. (B) Dual-luciferase reporter assays were performed to measure the luciferase activities. * * P<0.01 vs. mimic control. (C) Inhibitor control or miR-15a-5p inhibitor was transfected into RAW264.7 macrophages for 48 h to detect the mRNA levels of miR-15a-5p. Control-siRNA or TNIP2-siRNA was transfected into RAW264.7 macrophages for 48 h to detect the TNIP2 (D) mRNA and (E) protein levels. Following transfection with miR-15a-5p inhibitor, inhibitor control, or miR-15a-5p inhibitor + TNIP2-siRNA, the (F) mRNA and (G) protein expression level of TNIP2 in RAW264.7 macrophages was measured. ## P<0.01 vs. inhibitor control; && P<0.01 vs. control-siRNA; $$ P<0.01 vs. inhibitor. miR, microRNA; MUT, mutant; LPS, lipopolysaccharide; siRNA, small interfering RNA; TNIP, tumor necrosis factor-α induced protein 3-interacting protein; WT, wild-type; UTR, untranslated region.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Binding Assay, Luciferase, Transfection, Expressing, Mutagenesis, Small Interfering RNA

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: Expression of TNIP2 is suppressed in RAW264.7 macrophages following LPS treatment. (A) The mRNA expression levels of TNIP2 were reduced in RAW264.7 macrophages treated with LPS. (B) The protein levels of TNIP2 were detected by western blot analysis in RAW264.7 macrophages following LPS treatment. * * P<0.01 vs. control. LPS, lipopolysaccharide; TNIP, tumor necrosis factor-α induced protein 3-interacting protein.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Expressing, Western Blot

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: miR-15a-5p downregulation suppresses the LPS-induced inflammatory factors released in RAW264.7 macrophages. RAW264.7 macrophage cells were transfected with or without inhibitor control, miR-15a-5p inhibitor or miR-15a-5p inhibitor + TNIP2-siRNA for 48 h, and cells were subsequently stimulated with 1 µg/ml LPS for 4 h. The expression levels of inflammatory factors (A) IL-1β, (B) IL-6 and (C) TNF-α in cells from the various treatment groups were detected using ELISAs. * * P<0.01 vs. control; ## P<0.01 vs. LPS+inhibitor control; && P<0.01 vs. LPS+inhibitor. LPS, lipopolysaccharide; miR, microRNA; IL, interleukin; siRNA, small interfering RNA; TNF, tumor necrosis; TNIP, TNF-α induced protein 3-interacting protein.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Transfection, Expressing, Small Interfering RNA

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: miR-15a-5p inhibitor inhibits LPS-induced NF-κ activation in RAW264.7 macrophages and TNIP2-siRNA reverses the effects. RAW264.7 macrophage cells were transfected with or without inhibitor control, miR-15a-5p inhibitor or miR-15a-5p inhibitor + TNIP2-siRNA for 48 h, and cells were stimulated with 1 µg/ml LPS for 4 h. (A) Protein expression level of p-p65 and p65 was detected using western blot assays. (B) The ratio of p-p65/p65. * * P<0.01 vs. control; ## P<0.01 vs. LPS+inhibitor control; && P<0.01 vs. LPS+inhibitor. LPS, lipopolysaccharide; miR, microRNA; p, phosphorylated; siRNA, small interfering RNA; TNIP, tumor necrosis factor-α induced protein 3-interacting protein.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Activation Assay, Transfection, Expressing, Western Blot, Small Interfering RNA

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: Effect of miR-15a-5p inhibitor and TNIP2-siRNA on miR-15a-5p and TNIP2 expression in mice. (A) The level of miR-15a-5p in the serum of mice was detected using RT-qPCR. (B) The mRNA level of TNIP2 in the serum of mice was detected using RT-qPCR. * * P<0.01 vs. inhibitor control; ## P<0.01 vs. control-siRNA. miR, microRNA; siRNA, small interfering RNA; RT-qPCR, reverse transcription-quantitative PCR.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Expressing, Quantitative RT-PCR, Small Interfering RNA, Real-time Polymerase Chain Reaction

Journal: Experimental and Therapeutic Medicine

Article Title: microRNA-15a-5p participates in sepsis by regulating the inflammatory response of macrophages and targeting TNIP2

doi: 10.3892/etm.2020.8547

Figure Lengend Snippet: TNIP2-siRNA eliminates the effects of miR-15a-5p inhibitor in LPS-induced septic mice. The serum (A) IL-1β, (B) IL-6 and (C) TNF-α levels were evaluated using ELISAs. The serum (D) Cr, (E) BUN, (F) ALT and (G) AST levels were evaluated in the various treatment groups. * * P<0.01 vs. LPS+inhibitor control; ## P<0.01 vs. LPS+inhibitor. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatine; LPS, lipopolysaccharide; miR, microRNA; IL, interleukin; siRNA, small interfering RNA; TNF, tumor necrosis factor; TNIP, TNF-α induced protein 3-interacting protein.

Article Snippet: For treatment, the inhibitor control (80 mg/kg/day; 5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), miR-15a-5p inhibitor (80 mg/kg/day; Guangzhou RiboBio Co., Ltd.) or miR-15a-5p inhibitor (80 mg/kg/day; 5'-CACUGGUACAAGGGUUGGGAGA-3'; Shanghai GenePharma Co., Ltd.) + TNIP2-siRNA (80 mg/kg/day) were injected by caudal vein for 3 consecutive days as previously described , followed by LPS (10 mg/kg) injection at 24 h following the last administration.

Techniques: Small Interfering RNA